Sensei will use about $30 million to $40 million for the clinical development of its lead program, SNS-301, a vaccine that targets the tumor antigen aspartate beta hydroxylase, according to a ...

Story Continues OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer 917-497-7560 Business Development & Investor Relations Paul Spencer +44 (0)20 7495 2379 and ...

LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial By James Waldron Nov 14, 2024 9:38am Sensei Biotherapeutics layoffs checkpoint inhibitors Oncology ...

OKYO Pharma Ltd (the "Company"), a biotechnology firm specializing in biological products with a current market capitalization of $36.54 million, announced today that it has obtained $1.4 million ...